Lung Biotechnology PBC

Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

Role: collaborator

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

Role: collaborator

Porcine Kidney Xenotransplantation in Patients With End-Stage Kidney Disease

Role: collaborator

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

Role: collaborator

Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH

Role: collaborator

Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)

Role: collaborator

Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)

Role: lead

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

Role: lead

Beraprost-314d Added-on to Tyvaso® (BEAT)

Role: lead

A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients

Role: lead

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

Role: lead

Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients

Role: lead

Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Role: lead

A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor

Role: lead